Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2019-08-23 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Gilead en Galapagos ronden de closing van hun baanbrekende R&D-samenwerking af
Regulatory Filings Classification · 95% confidence The document is a press release announcing the closing of a global R&D collaboration agreement between Gilead Sciences and Galapagos NV. It details the financial terms (upfront payments and equity investment), regulatory approvals, and provides updated share capital information. While it contains financial data, it is an announcement of a corporate transaction (M&A/Partnership) rather than a formal financial report or a simple report publication announcement. Given the nature of the strategic partnership and capital structure change, it fits best under the 'Regulatory Filings' category as a general corporate announcement.
2019-08-23 Dutch
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a global research and development collaboration agreement between Gilead Sciences and Galapagos NV. It details the financial terms (upfront license fee and equity investment) and regulatory approvals. Crucially, the document concludes with an 'Attachment' section providing a link to a PDF version, which aligns with the 'Menu vs Meal' rule for a Report Publication Announcement (RPA). While it contains corporate information, its primary function as a short, public-facing announcement of a completed transaction with a link to the full document classifies it as an RPA.
2019-08-23 English
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a global research and development collaboration agreement between Gilead Sciences and Galapagos NV. It details the financial terms (upfront license fee and equity investment) and regulatory approvals. Crucially, the document concludes with an 'Attachment' section providing a link to a PDF version, which aligns with the 'Menu vs Meal' rule for a Report Publication Announcement (RPA). While it contains corporate information, its primary function as a short, public-facing announcement of a completed transaction with a link to the full document classifies it as an RPA.
2019-08-23 English
Gilead en Galapagos ronden de closing van hun baanbrekende R&D-samenwerking af
Regulatory Filings Classification · 95% confidence The document is a press release announcing the closing of a global R&D collaboration agreement between Gilead Sciences and Galapagos NV. It details the financial terms (upfront payments and equity investment), regulatory approvals, and provides updated share capital information. While it contains financial data, it is an announcement of a corporate transaction (M&A/Partnership) rather than a formal financial report or a simple report publication announcement. Given the nature of the strategic partnership and capital structure change, it fits best under the 'Regulatory Filings' category as a general corporate announcement.
2019-08-23 Dutch
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of a global research and development collaboration agreement between Gilead Sciences and Galapagos NV. It details the financial terms (upfront license fee and equity investment) and regulatory approvals. Crucially, the document concludes with an 'Attachment' section providing a link to a PDF version, which aligns with the 'Menu vs Meal' rule for a Report Publication Announcement (RPA). While it contains corporate information, its primary function as a short, public-facing announcement of a completed transaction with a link to the full document classifies it as an RPA.
2019-08-23 English
Gilead en Galapagos ronden de closing van hun baanbrekende R&D-samenwerking af
Regulatory Filings Classification · 95% confidence The document is a press release announcing the closing of a global R&D collaboration agreement between Gilead Sciences and Galapagos NV. It details the financial terms (upfront payments and equity investment), regulatory approvals, and provides updated share capital information. While it contains financial data, it is an announcement of a corporate transaction (M&A/Partnership) rather than a formal financial report or a simple report publication announcement. Given the nature of the strategic partnership and capital structure change, it fits best under the 'Regulatory Filings' category as a general corporate announcement.
2019-08-23 Dutch

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.